PL3169361T3 - Kompozycje do leczenia nowotworu z użyciem związków antagonistycznych wiązania osi pd-1 i inhibitorów mek - Google Patents

Kompozycje do leczenia nowotworu z użyciem związków antagonistycznych wiązania osi pd-1 i inhibitorów mek

Info

Publication number
PL3169361T3
PL3169361T3 PL15747647T PL15747647T PL3169361T3 PL 3169361 T3 PL3169361 T3 PL 3169361T3 PL 15747647 T PL15747647 T PL 15747647T PL 15747647 T PL15747647 T PL 15747647T PL 3169361 T3 PL3169361 T3 PL 3169361T3
Authority
PL
Poland
Prior art keywords
compositions
treating cancer
axis binding
mek inhibitors
binding antagonists
Prior art date
Application number
PL15747647T
Other languages
English (en)
Polish (pl)
Inventor
Melissa Junttila
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PL3169361T3 publication Critical patent/PL3169361T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL15747647T 2014-07-15 2015-07-15 Kompozycje do leczenia nowotworu z użyciem związków antagonistycznych wiązania osi pd-1 i inhibitorów mek PL3169361T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462024988P 2014-07-15 2014-07-15
PCT/US2015/040582 WO2016011160A1 (en) 2014-07-15 2015-07-15 Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors
EP15747647.4A EP3169361B1 (en) 2014-07-15 2015-07-15 Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors

Publications (1)

Publication Number Publication Date
PL3169361T3 true PL3169361T3 (pl) 2019-11-29

Family

ID=53783950

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15747647T PL3169361T3 (pl) 2014-07-15 2015-07-15 Kompozycje do leczenia nowotworu z użyciem związków antagonistycznych wiązania osi pd-1 i inhibitorów mek

Country Status (17)

Country Link
US (3) US10946093B2 (Direct)
EP (2) EP3563870A1 (Direct)
JP (2) JP6673896B2 (Direct)
KR (1) KR20170026630A (Direct)
CN (2) CN106573060A (Direct)
AR (1) AR101210A1 (Direct)
AU (1) AU2015289672A1 (Direct)
BR (1) BR112017000672A2 (Direct)
CA (1) CA2954508A1 (Direct)
ES (1) ES2742500T3 (Direct)
IL (2) IL250021B (Direct)
MX (1) MX2017000546A (Direct)
PL (1) PL3169361T3 (Direct)
RU (1) RU2733735C2 (Direct)
SG (2) SG11201700074YA (Direct)
WO (1) WO2016011160A1 (Direct)
ZA (1) ZA201701109B (Direct)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI835048B (zh) 2011-08-01 2024-03-11 美商建南德克公司 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer
SG11201700074YA (en) 2014-07-15 2017-02-27 Genentech Inc Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
AU2016294440B2 (en) 2015-07-13 2022-10-13 Cytomx Therapeutics, Inc Anti-PD-1 antibodies, activatable anti-PD-1 antibodies, and methods of use thereof
JP6949030B2 (ja) 2016-01-08 2021-10-13 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｐｄ−１軸結合アンタゴニスト及び抗ｃｅａ／抗ｃｄ３二重特異性抗体を用いたｃｅａ陽性がんの治療方法
US10568870B2 (en) * 2016-04-07 2020-02-25 Chemocentryx, Inc. Reducing tumor burden by administering CCR1 antagonists in combination with PD-1 inhibitors or PD-L1 inhibitors
WO2017202744A1 (en) * 2016-05-26 2017-11-30 Merck Patent Gmbh Pd-1 / pd-l1 inhibitors for cancer treatment
KR20190017767A (ko) * 2016-06-10 2019-02-20 노파르티스 아게 C-raf 억제제의 치료적 용도
EP3558360A1 (en) * 2016-12-22 2019-10-30 F. Hoffmann-La Roche AG Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
CN108503691B (zh) * 2017-02-25 2021-07-23 复旦大学 一种人pd-l1蛋白高亲和性肽及其应用
ES2977788T3 (es) 2017-04-20 2024-08-30 Adc Therapeutics Sa Terapia combinada con un conjugado de anticuerpo anti-AXL y fármaco
BR112019021680A2 (pt) 2017-04-20 2020-05-12 Adc Therapeutics Sa Terapia de combinação com conjugado anticorpo-fármaco anti-cd25??
DK3630112T3 (da) 2017-06-02 2024-04-22 Bayer Healthcare Llc Kombination af regorafenib og nivolumab til behandling af cancer
US11318211B2 (en) 2017-06-14 2022-05-03 Adc Therapeutics Sa Dosage regimes for the administration of an anti-CD19 ADC
WO2019023786A1 (en) 2017-08-01 2019-02-07 University Health Network COMBINED THERAPIES FOR THE INHIBITION OF TTK PROTEIN KINASE
BR112020006371A2 (pt) * 2017-10-13 2020-09-29 Merck Patent Gmbh combinação de um inibidor de parp e um antagonista de ligação de eixo de pd-1
RU2020126340A (ru) * 2018-01-10 2022-02-10 Аррэй Байофарма Инк. Способы и комбинированное терапевтическое средство для лечения рака
SG11202010469QA (en) 2018-05-23 2020-11-27 Adc Therapeutics Sa Molecular adjuvant
CN119955743A (zh) * 2018-09-10 2025-05-09 上海锦斯生物技术有限公司 修饰的溶瘤病毒、其组合物和用途
CN109053891B (zh) 2018-09-17 2021-12-21 苏州泓迅生物科技股份有限公司 一种抗pd-l1抗体及其制备方法和应用
CN109879855B (zh) * 2019-03-26 2021-01-05 中国医学科学院医药生物技术研究所 靶向肿瘤细胞表面pd-l1分子的抑制剂及其应用
GB201917254D0 (en) 2019-11-27 2020-01-08 Adc Therapeutics Sa Combination therapy
CN110981943B (zh) * 2019-12-02 2021-08-03 清华大学 多肽及其在制备药物中的用途和药物
CA3189383A1 (en) * 2020-07-13 2022-01-20 Verastem, Inc. Combination therapy for treating abnormal cell growth
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
JPWO2023008462A1 (Direct) * 2021-07-27 2023-02-02
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
WO1984003506A1 (en) 1983-03-08 1984-09-13 Commw Serum Lab Commission Antigenically active amino acid sequences
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
NZ215865A (en) 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5571689A (en) 1988-06-16 1996-11-05 Washington University Method of N-acylating peptide and proteins with diheteroatom substituted analogs of myristic acid
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5663143A (en) 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2050918A1 (en) 1990-01-12 1991-07-13 Raju Kucherlapati Generation of xenogeneic antibodies
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0533838B1 (en) 1990-06-11 1997-12-03 NeXstar Pharmaceuticals, Inc. Nucleic acid ligands
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU668347B2 (en) 1990-11-21 1996-05-02 Torrey Pines Institute For Molecular Studies Synthesis of equimolar multiple oligomer mixtures, especially of oligopeptide mixtures
EP0564531B1 (en) 1990-12-03 1998-03-25 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
EP0617706B1 (en) 1991-11-25 2001-10-17 Enzon, Inc. Multivalent antigen-binding proteins
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
DK1500329T3 (da) 1996-12-03 2012-07-09 Amgen Fremont Inc Humane antistoffer, der specifikt binder TNF-alfa
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
WO2002017952A2 (en) 2000-09-01 2002-03-07 Van Andel Institute Inhibition of mitogen-activated protein kinase (mapk) pathway: a selective therapeutic strategy against melanoma
NZ518726A (en) 2001-05-09 2004-06-25 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
DE60330227D1 (de) 2002-03-13 2010-01-07 Array Biopharma Inc N3-alkylierte benzimidazol-derivate als mek-hemmer
US20040209930A1 (en) 2002-10-02 2004-10-21 Carboni Joan M. Synergistic methods and compositions for treating cancer
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
CA2502413A1 (en) 2002-11-01 2004-05-21 The Regents Of The University Of Colorado, A Body Corporate Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry
WO2004045617A1 (en) 2002-11-15 2004-06-03 Warner-Lambert Company Llc Combination chemotherapy comprising a mek inhibitor and capecitabine for treating cancer
DE602005004286T2 (de) 2004-06-11 2009-01-02 Japan Tobacco Inc. 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyridoä2,3-düpyrimidinderivate und verwandte verbindungen zur behandlung von krebs
TW200639163A (en) 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
KR101498834B1 (ko) 2005-05-09 2015-03-05 오노 야꾸힝 고교 가부시키가이샤 예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법
PT1893612E (pt) 2005-06-22 2011-11-21 Plexxikon Inc Derivados de pirrolo [2,3-b]piridina como inibidores de proteína quinase
HRP20080053A2 (hr) 2005-07-01 2009-08-31 Medarex Ljudska monoklonska protutijela na ligand 1 za programiranu smrt stanice (pd-l1)
SI1934174T1 (sl) 2005-10-07 2011-08-31 Exelixis Inc Inhibitorji MEK in postopki za njihovo uporabo
US7612212B2 (en) 2006-02-22 2009-11-03 Hoffmann-La Roche Inc. Substituted hydantoins
AU2007286808B2 (en) 2006-08-21 2012-12-06 Genentech, Inc. Aza-benzofuranyl compounds and methods of use
WO2008101840A1 (en) 2007-02-23 2008-08-28 F. Hoffmann-La Roche Ag Combination of erlotinib and mek-inhibitors for inhibiting proliferation of tumor cells
CA2695956A1 (en) 2007-08-16 2009-02-19 F. Hoffmann-La Roche Ag Substituted hydantoins
CA2705452C (en) 2007-11-12 2016-05-31 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
CN101951959A (zh) 2007-11-30 2011-01-19 百时美施贵宝公司 抗b7h4单克隆抗体-药物缀合物和使用方法
RU2441004C1 (ru) 2007-12-19 2012-01-27 Дженентек, Инк. 5-анилиноимидазопиридины и способы их применения
CN104548091A (zh) 2008-02-11 2015-04-29 治疗科技公司 用于肿瘤治疗的单克隆抗体
ES2400202T3 (es) 2008-02-29 2013-04-08 Array Biopharma, Inc. Inhibidores de RAF de pirazol[3,4-B]piridina
JP2011513330A (ja) 2008-02-29 2011-04-28 アレイ バイオファーマ、インコーポレイテッド Ｒａｆ阻害化合物およびその使用方法
CA2716947A1 (en) 2008-02-29 2009-09-11 Array Biopharma Inc. Imidazo [4,5-b] pyridine derivatives used as raf inhibitors
CA2716949A1 (en) 2008-02-29 2009-09-11 Array Biopharma Inc. N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
MX336723B (es) 2008-07-11 2016-01-28 Novartis Ag Combinacion de (a) un inhibidor de fosfoinositido 3-cinasa y (b) un modulador de la ruta de ras/raf/mek.
EP2662383A1 (en) 2008-08-25 2013-11-13 Amplimmune, Inc. PD-I antagonists and methods for treating infectious disease
JP5798919B2 (ja) 2008-08-25 2015-10-21 アンプリミューン、インコーポレーテッドＡｍｐｌｉｍｍｕｎｅ， Ｉｎｃ． Ｐｄ−１アンタゴニストの組成物および使用方法
WO2010056735A1 (en) 2008-11-11 2010-05-20 The Trustees Of The University Of Pennsylvania Compositions and methods for inhibiting an oncogenic protein to enhance immunogenicity
CA3120172A1 (en) 2008-12-09 2010-07-08 Genentech, Inc. Anti-pd-l1 antibodies and their use to enhance t-cell function
PH12012500709A1 (en) 2009-10-12 2012-10-29 Hoffmann La Roche Combinations of a pi3k inhibitor and a mek inhibitor
CA2779424A1 (en) 2009-11-06 2011-05-12 Infinity Pharmaceuticals, Inc. Oral formulations of a hedgehog pathway inhibitor
EP2499486A4 (en) 2009-11-13 2013-11-27 Infinity Pharmaceuticals Inc COMPOSITIONS, KITS AND METHODS OF IDENTIFICATION, ASSESSMENT, PREVENTION AND THERAPY OF CANCER
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
HUE037159T2 (hu) 2009-11-24 2018-08-28 Medimmune Ltd Targetált kötõdõ ágensek B7-H1 ellen
PT2542256T (pt) 2010-03-04 2019-09-05 Macrogenics Inc Anticorpos reativos com b7-h3, fragmentos imunologicamente ativos dos mesmos e sua utilização
TWI835048B (zh) 2011-08-01 2024-03-11 美商建南德克公司 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法
EA201490879A1 (ru) 2011-10-28 2014-08-29 Дженентек, Инк. Терапевтические комбинации и способы лечения меланомы
BR112015022019A2 (pt) 2013-03-14 2017-08-29 Genentech Inc Anticorpos isolados, ácido nucleico, célula hospedeira, método de produção de anticorpos, imunoconjugado, formulação farmacêutica, métodos de tratamento de indivíduos, de inibição da proliferação de células, de detecção de b7-h4 humano e de detecção de câncer
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
JP2016520643A (ja) 2013-06-03 2016-07-14 ノバルティス アーゲー 抗ｐｄ−ｌ１抗体とｍｅｋ阻害薬および／またはｂｒａｆ阻害薬の組み合わせ物
SG11201700074YA (en) 2014-07-15 2017-02-27 Genentech Inc Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors

Also Published As

Publication number Publication date
AU2015289672A1 (en) 2017-03-02
CN116617401A (zh) 2023-08-22
US10946093B2 (en) 2021-03-16
US20240390488A1 (en) 2024-11-28
JP6673896B2 (ja) 2020-03-25
SG10202007111TA (en) 2020-09-29
SG11201700074YA (en) 2017-02-27
AR101210A1 (es) 2016-11-30
ES2742500T8 (es) 2020-02-27
RU2017102926A3 (Direct) 2018-12-21
IL250021A0 (en) 2017-03-30
MX2017000546A (es) 2017-03-08
EP3169361A1 (en) 2017-05-24
JP2020059721A (ja) 2020-04-16
JP2017522307A (ja) 2017-08-10
WO2016011160A1 (en) 2016-01-21
RU2733735C2 (ru) 2020-10-06
ZA201701109B (en) 2021-07-28
EP3169361B1 (en) 2019-06-19
EP3563870A1 (en) 2019-11-06
KR20170026630A (ko) 2017-03-08
CN106573060A (zh) 2017-04-19
US20220105180A1 (en) 2022-04-07
ES2742500T3 (es) 2020-02-14
CA2954508A1 (en) 2016-01-21
IL250021B (en) 2020-08-31
IL276314A (en) 2020-09-30
BR112017000672A2 (pt) 2017-11-14
US20170112925A1 (en) 2017-04-27
RU2017102926A (ru) 2018-08-15

Similar Documents

Publication Publication Date Title
IL276314A (en) Preparations for the treatment of cancer using PD-1 axis binding antagonists and MEK inhibitors
IL304820A (en) Preparations and methods for the treatment of cancer
AU2022231657A1 (en) Compositions and Methods for Treating Cancer
IL267247B (en) Compositions and methods for treating cancer
IL266053A (en) Preparations and methods for the treatment of ezh2-mediated cancer
IL252610A0 (en) Methods and preparations for the treatment of cancer
IL246679A0 (en) Materials and preparations for the treatment of tumors that express egfr
IL247102B1 (en) Combination of pd-1 antagonist and ido1 inhibitor for cancer treatment
PT3200815T (pt) Métodos e composições para o tratamento de cancro
IL250715A0 (en) Preparations and methods for the treatment of cultural disorders
IL256523A (en) Compositions and methods for treating cancer
PT3189074T (pt) Composições e métodos para tratar e prevenir a inflamação
IL255638A (en) Compositions and methods for treating cancer
SG10202013112YA (en) Zinc-gamma-pga compositions and methods for treating cancer
EP3220908A4 (en) Compositions and methods for treating endometriosis
EP3154544A4 (en) Compositions and methods for treating cancers
ZA201703771B (en) Compositions and methods for treating hyperkalemia
ZA201605109B (en) Compositions and methods for treating neutropenia
EP3104896A4 (en) Compositions and methods for treating liver injury
ZA201802268B (en) Methods and compositions for preventing or treating cancer
SG10201912086QA (en) Compositions and methods for treating cancer
EP3268028A4 (en) Compositions and methods for treating cancer
EP3160591A4 (en) Compositions and methods for treating cancer
GB201407949D0 (en) Compositions and methods for treating biofilms